BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Calithera Biosciences, Inc. Presents Preclinical Data For CB-839 At The 55th American Society of Hematology Annual Meeting


12/10/2013 7:12:53 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 55th American Society of Hematology (ASH) Annual Meeting. CB-839 is a potent, selective, orally available glutaminase inhibitor that interferes with tumor metabolism and blocks cancer cell growth and survival.

"Glutaminase is an enzyme responsible for converting glutamine into a form that can be used by cells for energy production and the synthesis of macromolecules. Many tumor types rely on glutamine for growth and survival, so with CB-839, we hope to block glutaminase activity and thereby starve the tumor of its energy source," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera Biosciences. "The data being presented at ASH demonstrate that CB-839 is a potent inhibitor of glutaminase and provide strong evidence for its potential therapeutic benefit in treating patients with hematologic malignancies. We look forward to advancing CB-839 into Phase 1 studies in hematological patient populations early next year."

Calithera researchers evaluated the anti-tumor activity of CB-839 in diverse cell lines of B-cell malignancies including multiple myeloma, acute lymphocytic leukemia, and non-Hodgkin's lymphoma. Treatment with CB-839 had anti-proliferative effects on the majority of tumor cell lines evaluated (36 out of 44) and induced cell death in a significant fraction of those cell lines. In a xenograft model of multiple myeloma, oral twice-daily dosing of CB-839 resulted in a 70 percent inhibition of tumor growth. Anti-tumor activity was dose dependent and was correlated with tumor glutamine accumulation, tumor glutamate decrease, and glutaminase inhibition. Efficacious doses of CB-839 were well tolerated with no effects on hematologic cell counts or body weight. The strong correlation between glutamine dependence and sensitivity to CB-839 in B cell tumor lines suggests that glutamine supports cell growth and survival in these tumors through metabolism of glutamine by glutaminase. Calithera plans to advance CB-839 into Phase 1 clinical trials in patients with advanced solid and hematological tumors in early 2014.

Calithera's in vitro and in vivo data on CB-839 were presented in a poster entitled, "Antitumor Activity of the Glutaminase Inhibitor CB-839 in Hematological Malignancies," (Abstract #4226), during the Chemical Biology and Experimental Therapeutics on December 9, 2013.

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival. The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development. The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics. Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing. Calithera Biosciences is a privately held company located in South San Francisco, CA. For more information, please visit www.calithera.com.

SOURCE Calithera Biosciences



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES